检索结果-南通市图书馆

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 514-525页

作者： Shaoyan Lin Jian Yue Xiuwen Guan Peng Yuan Jiayu Wang Yang Luo Ying Fan Ruigang Cai Qiao Li Shanshan Chen Pin Zhang Qing Li Fei Ma binghe xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeNo.17Panjiayuan NanliChaoyang DistrictBeijing 100021P.R.China Department of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100021P.R.China

Background:Breast cancer is a global problem,and a large number of new cases are diagnosed every ***-abine is effective in patients with metastatic breast cancer(MBC).Hand-foot syndrome(HFS)is a common adverse effect of *** this study,we investigated the association between single nucleotide polymorphisms(SNPs)in genes involved in capecitabine metabolism pathways and capecitabine-induced HFS in Chinese patients with MBC to identify some predictive genetic ***:We selected 3 genes involved in capecitabine metabolism and screened genetic variants in these target *** genotyped a total of 22 SNPs in the thymidylate synthase gene(TYMS),the methylene tetrahydrofolate reductase gene(MTHFR),and the ribonucleotide reductase M1 gene(RRM1)in 342 MBC patients treated with capecit-abine-based *** genotype distributions of each SNP in patients with and without HFS were assessed using Pearson’sχ^(2)test,and the relationship between HFS and genotypes of SNPs was determined using logistic regression *** association between SNPs and their corresponding gene expression was analyzed using the Blood expression quantitative trait loci(eQTL)browser online ***:We found 4 positive sites for HFS in the TYMS and MTHFR genes:TYMS rs2606241(P=0.022),TYMS rs2853741(P=0.019),MTHFR rs3737964(P=0.029),and MTHFR rs4846048(P=0.030).Logistic regression analyses showed that the genotype AG of MTHFR rs3737964[odds ratio(OR)=0.54,95%confidence interval(CI)0.31-0.97,P=0.038]and MTHFR rs4846048(OR=0.54,95%CI 0.30-0.98,P=0.042)were protective factors of HFS,whereas the genotype CT of TYMS rs2853741(OR=2.25,95%CI 1.31-3.87,P=0.012)increased the risk of *** association between the genotype GT of TYMS rs2606241(OR=1.27,95%CI 0.73-2.23,P=0.012)and HFS was *** eQTL analyses confirmed that the alleles of rs3737964 and rs4846048 affected the gene expression levels of MTHFR in ***:We have identified four potentiall

关键词： Capecitabine Polymorphism Metastatic breast cancer Hand-foot syndrome TYMS MTHFR

Advances on anticancer new drugs in China and the USA in 2020:from ongoing trial to drug approval

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of the National Cancer Center 2021年第4期1卷 147-152页

作者： Huiyao Huang Huilei Miao Jun Wang Dawei Wu Qi Lei Shuhang Wang Hong Fang Yu Tang Ning Li binghe xu Jie He Department of Clinical Trial Center National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina National Center for Drug Evaluation National Medical Products AdministrationBeijingChina

Objectives:To describe and compare the research and development(R&D)pipeline of cancer new drugs and newly approved drugs in China and the USA in 2020,thus to provide decision-making evidence for related ***:Clinical trials and tested cancer new drugs information in China and the USA were respectively ac-quired from Information Disclosure Platform for Drug Clinical Studies and Trialtrove *** approval was tracked from the official *** comparison in terms of initiated trials and drugs were conducted between the two ***:In 2020,577 trials on 335 cancer new drugs were registered in China,accounting for 22.6%of all clinical drug trials,while in the USA,916 trials on 678 cancer new drug trials were captured,accounting for 19.9%of the ***,a lower proportion of earlier phase(76.9%vs 87.4%),global(17.7%vs 39.0%),and top 20 pharmaceutics contribution(15.8%vs 43.2%)were found for cancer drug trials initiated in *** fight against solid tumor took top billing in both countries,and the different distribution of cancer indications associated with cancer spectrum was also *** with the USA,more targeted agents(87.5%vs 77.0%,P<0.001)and less immune agents(30.7%vs 41.6%,P<0.001)were tested in *** addition,16 and 18 anticancer new drugs were approved in China and the USA,with 6(37.5%)and 17(94.4%)drugs being firstly approved worldwide,*** them,32 drugs were granted by at least one expedited program,and 31 drugs were approved based on evidence from surrogate endpoints.A total of 17 cancer types were covered,and only one drug was targeted on digestive cancers,including gastric,liver,and esophageal ***:R&D of anticancer new drugs is substantial,and great progress has been made in both China and the USA in *** difference and gap between China and the USA highlight that more efforts should be paid to anticancer drug R&D on innovative agents and cancers unique to Ch

关键词： Neoplasms Clinical trial Drug China USA

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2018年第1期38卷 31-38页

作者： Meiying Li Fei Ma Jiayu Wang Qing Li Pin Zhang Peng Yuan Yang Luo Ruigang Cai Ying Fan Shanshan Chen Qiao Li binghe xu Department of Medical Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeNo.17Panjiayuan NanliChaoyang DistrictBeijing 100021P.R.China

Background:Autophagy plays a crucial role in chemotherapy resistance of triple-negative breast cancer(TNBC).Hence,autophagy-related gene 5(ATG5),an essential molecule involved in autophagy regulation,is presumably associated with recurrence of *** study was aimed to investigate the potential influence of single-nucleotide polymorphisms in ATG5 on the disease-free survival(DFS)of early-stage TNBC patients treated with anthracycline-and/or taxane-based ***:We genotyped ATG5 SNP rs473543 in a cohort of 316 TNBC patients treated with anthracycline-and/or taxane-based chemotherapy using the sequenom’s MassARRAY ***-Meier survival analysis and Cox proportional hazard regression analysis were used to analyze the association between ATG5 rs473543 genotypes and the clinical outcome of TNBC ***:Three genotypes,AA,GA,and GG,were detected in the rs473543 of ATG5 *** distribution of ATG5 rs473543 genotypes was significantly different between patients with and without recurrence(P=0.024).Kaplan-Meier survival analysis showed that patients carrying A allele of ATG5 rs473543 had an increased risk of recurrence and shorter DFS compared with those carrying the variant genotype GG in rs473543(P=0.034).In addition,after adjust-ing for clinical factors,multivariate Cox regression analyses revealed that the AA/GA genotype of rs473543 was an independent predictor for DFS(hazard risk[HR],1.73;95%confidence interval[CI],1.04-2.87;P=0.034).In addition,DFS was shorter in node-negative patients with the presence of A allele(AA/GA)than in those with the absence of A allele(P=0.027).Conclusion:ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early-stage TNBC patients who received anthracycline-and/or taxane-based regimens as adjuvant chemotherapy.

关键词： Autophagy-related gene 5 Triple-negative breast cancer Disease-free survival Anthracycline Taxanes

An immunogenic cell death-related signature for prediction of prognosis and response to immunotherapy in breast cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第4期137卷 487-489页

作者： Cong Li Fengzhu Guo Jingtong Zhai Xiaohan Liu Zhijun Li binghe xu Department of Medical Oncology National Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China Department of Medical Oncology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing 100730China Department of Histology and Embryology Basic Medical CollegeChina Medical UniversityShenyangLiaoning 110122China

To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer *** data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.

关键词： breast immunotherapy chemotherapy

An appropriate treatment interval does not afect the prognosis of patients with breast Cancer

在线全文

学校读者我要写书评

暂无评论

Holistic Integrative Oncology 2022年第1期1卷 127-133页

作者： Wei Gao Jiaxing Wang Sifei Yin Cuizhi Geng binghe xu East Tianshan Avenue Shijiazhuang 050035HebeiChina Department of Chemical and Systems Biology Stanford UniversityStanfordCalifornia 94305USA National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Purpose:Major public health emergencies may lead to delays or alterations in the treatment of patients with breast cancer at each stage of diagnosis and *** much do these delays and treatment changes afect treatment outcomes in patients with breast cancer?Methods:This review summarized relevant research in the past three decades and identifed the efect of delayed treatment on the prognosis of patients with breast cancer in terms of seeking medical treatment,neoadjuvant treatment,surgery,postoperative chemotherapy,radiotherapy,and targeted ***:Delay in seeking medical help for≥12weeks afected the *** treatment within 4 weeks of diagnosis did not afect patient *** neoadjuvant chemotherapy within 8 weeks after diagnosis,receiving surgical treatment at 8 weeks or less after the completion of neoadjuvant chemotherapy,and receiving radiotherapy 8 weeks after surgery did not afect patient *** chemotherapy did not increase the risk of relapse in patients with luminal A breast *** 4 weeks of delay in the start of postoperative chemotherapy in patients with luminal B,triple-negative,or HER2-positive breast cancer treated with trastuzumab will adversely afect the *** treatment delays in patients with HER2-positive breast cancer should not exceed 60days after surgery or 4months after *** within 8 weeks after surgery did not increase the risk of recurrence in patients with early breast cancer who were not undergoing adjuvant ***:Diferent treatments have diferent time sensitivities,and the careful evaluation and management of these delays will be helpful in minimizing the negative efects on patients.

关键词： Treatment delay Risk evaluation Prognosis Breast cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

乳腺癌靶向治疗的临床进展和未来

中国肿瘤临床 2017年第13期44卷 625-629页

作者：徐兵河国家癌症中心/中国医学科学院、北京协和医学院肿瘤医院内科北京市100021

靶向治疗是乳腺癌最重要的治疗手段之一。近年来针对不同亚型乳腺癌开发了越来越多的分子靶向治疗药物,这些药物的临床应用改善了乳腺癌的治疗效果,并不断改变乳腺癌的临床实践过程。如何克服肿瘤的耐药性以及开发出能够超越传统靶向药... 详细信息

靶向治疗是乳腺癌最重要的治疗手段之一。近年来针对不同亚型乳腺癌开发了越来越多的分子靶向治疗药物,这些药物的临床应用改善了乳腺癌的治疗效果,并不断改变乳腺癌的临床实践过程。如何克服肿瘤的耐药性以及开发出能够超越传统靶向药物疗效的新药是今后的重要研究方向。

关键词：乳腺癌人表皮生长因子受体2 激素受体靶向治疗

Dose-dense paclitaxel plus carboplatin *** and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2020年第4期32卷 485-496页

作者： Qing Li Jiani Wang Yuxin Mu Tongtong Zhang Ying Han Jiayu Wang Qiao Li Yang Luo Fei Ma Ying Fan Pin Zhang binghe xulj Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Objective:The objective of this open-label,randomized study was to compare dose-dense paclitaxel plus carboplatin(PCdd)with dose-dense epirubicin and cyclophosphamide followed by paclitaxel(ECdd-P)as an adjuvant chemotherapy for early triple-negative breast cancer(TNBC).Methods:We included Chinese patients with high recurrence risk TNBC who underwent primary breast cancer *** were randomly assigned to receive PCdd[paclitaxel 150 mg/m2 on d 1 and carboplatin,the area under the curve,(AUC)=3 on d 2]or ECdd-P(epirubicin 80 mg/m2 divided in 2 d and cyclophosphamide 600 mg/m2 on d 1 for 4 cycles followed by paclitaxel 175 mg/m2 on d 1 for 4 cycles)every 2 weeks with granulocyte colony-stimulating factor(G-CSF)*** primary endpoint was 3-year disease-free survival(DFS);the secondary endpoints were overall survival(OS)and ***:The intent-to-treat population included 143 patients(70 in the PCdd arm and 73 in the ECdd-P arm).Compared with the ECdd-P arm,the PCdd arm had significantly higher 3-year DFS[93.9%vs.79.1%;hazard ratio(HR)=0.310;95%confidence interval(95%CI),0.137-0.704;log-rank,P=0.005]and OS(98.5%vs.92.9%;HR=0.142;95%CI,0.060-0.825;log-rank,P=0.028).Worse neutropenia(grade 3/4)was found in the ECdd-P than the PCdd arm(47.9%V5.21.4%,P=0.001).Conclusions:PCdd was superior to ECdd-P as an adjuvant chemotherapy for early TNBC with respect to improving the 3-year DFS and *** also yielded lower hematological ***,PCdd might be a preferred regimen for early TNBC patients with a high recurrence risk.

关键词： Triple-negative breast cancer dose-dense adjuvant chemotherapy carboplatin paclitaxel

在线全文

学校读者我要写书评

暂无评论

乳腺癌辅助化疗的新概念

中国实用外科杂志 2006年第4期26卷 251-253页

作者：徐兵河中国医学科学院附属肿瘤医院内科北京100021

乳腺癌辅助化疗始于20世纪50年代后期。最初是在术中应用塞替哌以期消灭肿瘤细胞。此后，微转移概念为延长辅助化疔时间奠定了理论基础。从20世纪70年代的CMF方案到80年代的蒽环类和90年代的紫杉类药物以及近年来生物治疗与化疗的联合... 详细信息

乳腺癌辅助化疗始于20世纪50年代后期。最初是在术中应用塞替哌以期消灭肿瘤细胞。此后，微转移概念为延长辅助化疔时间奠定了理论基础。从20世纪70年代的CMF方案到80年代的蒽环类和90年代的紫杉类药物以及近年来生物治疗与化疗的联合应用，从常规用药到密集化疗，乳腺癌的辅助化疗取得了突飞猛进的发展。约100多组前瞻性随机临床试验的结果表明，术后辅助化疗可提高存活率、降低复发率和病死率，目前在世界范围内已得到广泛的认同和应用。

关键词：术后辅助化疗乳腺癌癌治疗前瞻性随机临床试验 20世纪紫杉类药物 CMF方案世界范围内肿瘤细胞术中应用

Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients:a prospective randomized phase II study

在线全文

学校读者我要写书评

暂无评论

Journal of the National Cancer Center 2023年第2期3卷 115-120页

作者： Nilupai Abudureheiyimu Yun Wu Qing Li Pin Zhang Fei Ma Peng Yuan Yang Luo Ying Fan Shanshan Chen Ruigang Cai Qiao Li Yiqun Han Hangcheng xu Yan Wang Jiayu Wang binghe xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Background:This study was conducted to evaluate the efficacy and safety of docetaxel/S-1(TS)compared with docetaxel/capecitabine(TX)as a first-line treatment for advanced breast ***:Patients with advanced metastatic breast cancer were randomly divided into the TS group(n=54)and the TX group(n=57)for first-line chemotherapy from August 2015 to April 2019(*** registration ***02947061).Following the completion of combination therapy,patients without progression received S-1 or capecitabine maintenance *** primary end point was progression-free survival(PFS).Results:Among 111 enrolled patients,the median PFS did not differ significantly between the TS group and the TX group(TS ***,9.0 vs.7.4 months,P=0.365,95%confidence interval[CI]:0.50-1.11,hazard ratio[HR]:0.75).There was also no statistically significant difference in median overall survival(OS)between the two groups(TS ***,40.2 vs.41.3 months,P=0.976).In addition,visceral metastasis and metastasis sites,such as the liver or lung,did not lead to a significant effect on PFS and *** two regimens showed no significant difference in adverse events,except hand-foot syndrome,which predominated in the TX group(38.6%vs.7.4%,P=0.001),and diarrhea(24.1%vs.3.6%,P=0.003)and elevation of aspartate aminotransferase(AST)/alanine aminotransferase(ALT)levels(14.8%vs.3.5%,P=0.049),which were more frequent in the TS ***:The TS and TX regimens demonstrated similar efficacy and safety for the first-line treatment of advanced breast *** TS regimen had fewer cases of severe hand-foot syndrome than the TX regimen,representing an effective alternative option to the TX *** studies are warranted to define the efficacy and safety of this strategy in real-world settings.

关键词： Advanced breast cancer Maintenance therapy Docetaxel Capecitabine S-1